Biomarkers · 2014 · 58 citations · 16 references
MedicineImmunologyOncologyCancer ImmunologyClinical ImmunologyInflammationCytokine BiologyCytokines In Tumor ImmunityImmuno-oncology BiomarkersLung CancerPulmonary InflammationComparative Diagnostic PerformanceDiagnostic Performance MetricsEnzyme-linked Immunosorbent Assay (Elisa)Inflammatory Cytokine ProfilesPrognostic BiomarkersPrognostic Marker AssessmentPrognostic Marker EvaluationT Helper 17 Immunity
OBJECTIVE: The aim of this study was to explore the clinical role of serum interleukin (IL)-17 in patients with non-small-cell lung cancer (NSCLC). MATERIALS AND METHOD: Serum specimens from 128 patients with NSCLC and 60 healthy controls were collected. The concentrations of IL-17 were measured using enzyme-linked immunosorbent assay. RESULTS: Serum IL-17 levels were higher in the NSCLC group in comparison with the control group (p < 0.01). With a cut-off value of 16 pg/ml, IL-17 showed a good diagnostic performance for NSCLC. Multivariate survival analysis indicated that IL-17 was an independent prognostic factor in NSCLC. CONCLUSION: Measurement of IL-17 might be a useful diagnostic and prognostic value for patients with NSCLC.
16
Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text
Muneo Numasaki, Mika Watanabe, Takashi Suzuki et al. · The Journal of Immunology · 2005 · 413 citations · Full text
Medicine, Immunology, Oncology +15
Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism
Fabrice Benchetrit, Arnaud Cirée, Virginie Vives et al. · Blood · 2002 · 344 citations · Full text
Life Sciences, Immunology, Oncology +14